A comprehensive view of Genmab A/S. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

INTERNATIONAL PATENT: BIONTECH SE, GENMAB A/S FILES APPLICATION FOR "MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE"
Published: November 20, 2023 by U.S. Fed News
INTERNATIONAL PATENT: GENMAB A/S, BIONTECH SE FILES APPLICATION FOR "BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY"
Published: November 20, 2023 by U.S. Fed News
INTERNATIONAL PATENT: GENMAB A/S, BIONTECH SE FILES APPLICATION FOR "BINDING AGENTS BINDING TO EPCAM AND CD137"
Published: September 25, 2023 by U.S. Fed News
INTERNATIONAL PATENT: GENMAB A/S, BIONTECH SE FILES APPLICATION FOR "MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION"
Published: April 17, 2023 by U.S. Fed News
INTERNATIONAL PATENT: GENMAB A/S, BIONTECH SE, MSD INTERNATIONAL BUSINESS GMBH FILES APPLICATION FOR "MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS"
Published: April 17, 2023 by U.S. Fed News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count